245528-23-8 Usage
Chemical class
Belongs to the class of indazoles, which are a group of organic compounds containing a fused indole and pyrazole ring system.
Structural features
Contains a carboxymethyl group (-CH2COOH) and an ethoxycarbonyl group (-COOCH2CH3) attached to the indazole ring.
Potential applications
Has potential applications in the field of organic synthesis, pharmaceuticals, and materials science.
Drug development
May have uses in the development of new drugs due to its unique structure and properties.
Building block
Can be used as a building block for the synthesis of other chemical compounds.
Research potential
Its unique structure and properties make it a promising candidate for further research and potential industrial applications.
Molecular weight
The molecular weight of 1-Carboxymethyl-5-ethoxycarbonylindazole is approximately 233.21 g/mol.
Solubility
The solubility of 1-Carboxymethyl-5-ethoxycarbonylindazole may vary depending on the solvent used, but it is generally expected to be more soluble in polar solvents like water or methanol.
Stability
The stability of 1-Carboxymethyl-5-ethoxycarbonylindazole can be influenced by factors such as temperature, light exposure, and the presence of other reactive substances. It is important to store and handle the compound according to recommended guidelines to maintain its stability and integrity.
Check Digit Verification of cas no
The CAS Registry Mumber 245528-23-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,5,5,2 and 8 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 245528-23:
(8*2)+(7*4)+(6*5)+(5*5)+(4*2)+(3*8)+(2*2)+(1*3)=138
138 % 10 = 8
So 245528-23-8 is a valid CAS Registry Number.
245528-23-8Relevant articles and documents
Integrin antagonists
-
, (2008/06/13)
This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
